What is Armored RNA Technology?
Armored RNA® and Armored DNA™ technologies stabilize and protect nucleic acids from nuclease degradation by packaging them in a protective protein coat. Armored reagents deliver several end-user benefits, including:
Optimized Workflow
Armored RNA, Armored RNA Quant and Armored DNA Quant controls can be added directly to human matrices as an exogenous internal control for extraction with most nucleic acid isolation methods and detection in molecular assays.
Flexibility
Nuclease-resistant protein coat can also be removed by heat lysis for direct detection as a positive run control. For Armored RNA Quant and Armored DNA Quant, analytical quantification is performed with a validated method referencing a NIST-traceable phosphate standard.
cGMP-Compliant Armored Molecular Controls
When designing molecular assays for diagnostic or clinical application, incorporating Current Good Manufacturing Practices (cGMP) control products is crucial to ensure assays align with regulatory requirements to produce accurate, reliable, and reproducible results.
Armored technology stabilizes and protects nucleic acids from nuclease degradation by packaging targets in a protective protein coat, providing a non-infectious molecular control that can monitor the complete molecular assay workflow from extraction to detection.
SARS-CoV-2
| Description | Configuration | Part # | cGMP |
|---|---|---|---|
| Targets the Nucleocapsid 1 and Nucleocapsid 2 regions of the CDC recommended Diagnostic Panel (CDC-006-00019). | 1x106 cp/mL 250μL | 52151 | ● |
| Target | Size | Sequence |
|---|---|---|
| N1N2 | 1105 | GAACAAACTAAAATGTCTGATAATGGACCCCAAAATCAGCGAAATGCACCCCGCATTACGTTTGGTGGACCCTCAGATTCAACTGGCAGTAAC CAGAATGGAGAACGCAGTGGGGCGCGATCAAAACAACGTCGGCCCCAAGGTTTACCCAATAATACTGCGTCTTGGTTCACCGCTCTCACTCA ACATGGCAAGGAAGACCTTAAATTCCCTCGAGGACAAGGCGTTCCAATTAACACCAATAGCAGTCCAGATGACCAAATTGGCTACTACCGAA GAGCTACCAGACGAATTCGTGGTGGTGACGGTAAAATGAAAGATCTCAGTCCAAGATGGTATTTCTACTACCTAGGAACTGGGCCAGAAGCTG GACTTCCCTATGGTGCTAACAAAGACGGCATCATATGGGTTGCAACTGAGGGAGCCTTGAATACACCAAAAGATCACATTGGCACCCGCAATCC TGCTAACAATGCTGCAATCGTGCTACAACTTCCTCAAGGAACAACATTGCCAAAAGGCTTCTACGCAGAAGGGAGCAGAGGCGGCAGTCAAGC CTCTTCTCGTTCCTCATCACGTAGTCGCAACAGTTCAAGAAATTCAACTCCAGGCAGCAGTAGGGGAACTTCTCCTGCTAGAATGGCTGGCAAT GGCGGTGATGCTGCTCTTGCTTTGCTGCTGCTTGACAGATTGAACCAGCTTGAGAGCAAAATGTCTGGTAAAGGCCAACAACAACAAGGCCAA ACTGTCACTAAGAAATCTGCTGCTGAGGCTTCTAAGAAGCCTCGGCAAAAACGTACTGCCACTAAAGCATACAATGTAACACAAGCTTTCGGCA GACGTGGTCCAGAACAAACCCAAGGAAATTTTGGGGACCAGGAACTAATCAGACAAGGAACTGATTACAAACATTGGCCGCAAATTGCACAAT TTGCCCCCAGCGCTTCAGCGTTCTTCGGAATGTCGCGCATTGGCATGGAAGTCACACCTTCGGGAACGTG |
SARS-CoV-2 Panel
| Description | Configuration | Part # | cGMP |
|---|---|---|---|
| Contains multiple regions of SARS-Cov-2 genome including nucleocapsid, envelope, RNA-dependent RNA polymerase, open reading frame 1, and human RNAse P as an internal control. | 1x106 cp/mL 250μL | 52153 |
| Target | Size | Sequence |
|---|---|---|
| N | 1105 | GAACAAACTAAAATGTCTGATAATGGACCCCAAAATCAGCGAAATGCACCCCGCATTACGTTTGGTGGACCCTCAGATTCAACTGGCAGTAAC CAGAATGGAGAACGCAGTGGGGCGCGATCAAAACAACGTCGGCCCCAAGGTTTACCCAATAATACTGCGTCTTGGTTCACCGCTCTCACTCAA CATGGCAAGGAAGACCTTAAATTCCCTCGAGGACAAGGCGTTCCAATTAACACCAATAGCAGTCCAGATGACCAAATTGGCTACTACCGAAGA GCTACCAGACGAATTCGTGGTGGTGACGGTAAAATGAAAGATCTCAGTCCAAGATGGTATTTCTACTACCTAGGAACTGGGCCAGAAGCTGGA CTTCCCTATGGTGCTAACAAAGACGGCATCATATGGGTTGCAACTGAGGGAGCCTTGAATACACCAAAAGATCACATTGGCACCCGCAATCCTG CTAACAATGCTGCAATCGTGCTACAACTTCCTCAAGGAACAACATTGCCAAAAGGCTTCTACGCAGAAGGGAGCAGAGGCGGCAGTCAAGCCT CTTCTCGTTCCTCATCACGTAGTCGCAACAGTTCAAGAAATTCAACTCCAGGCAGCAGTAGGGGAACTTCTCCTGCTAGAATGGCTGGCAATGG CGGTGATGCTGCTCTTGCTTTGCTGCTGCTTGACAGATTGAACCAGCTTGAGAGCAAAATGTCTGGTAAAGGCCAACAACAACAAGGCCAAACT GTCACTAAGAAATCTGCTGCTGAGGCTTCTAAGAAGCCTCGGCAAAAACGTACTGCCACTAAAGCATACAATGTAACACAAGCTTTCGGCAGAC GTGGTCCAGAACAAACCCAAGGAAATTTTGGGGACCAGGAACTAATCAGACAAGGAACTGATTACAAACATTGGCCGCAAATTGCACAATTTGC CCCCAGCGCTTCAGCGTTCTTCGGAATGTCGCGCATTGGCATGGAAGTCACACCTTCGGGAACGTG |
| E | 193 | TGTGCGTACTGCTGCAATATTGTTAACGTGAGTCTTGTAAAACCTTCTTTTTACGTTTACTCTCGTGTTAAAAATCTGAATTCTTCTAGAGTTCCT GATCTTCTGGTCTAAACGAACTAAATATTATATTAGTTTTTCTGTTTGGAACTTTAATTTTAGCCATGGCAGATTCCAACGGTACTATTACCGTTGA |
| RdRp | 787 | TGTAGAAAACCCTCACCTTATGGGTTGGGATTATCCTAAATGTGATAGAGCCATGCCTAACATGCTTAGAATTATGGCCTCACTTGTTCTTGC TCGCAAACATACAACGTGTTGTAGCTTGTCACACCGTTTCTATAGATTAGCTAATGAGTGTGCTCAAGTATTGAGTGAAATGGTCATGTGTGG CGGTTCACTATATGTTAAACCAGGTGGAACCTCATCAGGAGATGCCACAACTGCTTATGCTAATAGTGTTTTTAACATTTGTCAAGCTGTCACG GCCAATGTTAATGCACTTTTATCTACTGATGGTAACAAAATTGCCGATAAGTATGTCCGCAATTTACAACACAGACTTTATGAGTGTCTCTATAG AAATAGAGATGTTGACACAGACTTTGTGAATGAGTTTTACGCATATTTGCGTAAACATTTCTCAATGATGATACTCTCTGACGATGCTGTTGTGT GTTTCAATAGCACTTATGCAGTTGAACATGTTACCTTCTTCATCTACAATAAAATTGTTGATGAGCCTGAAGAACATGTCCAAATTCACACAATCG ACGGTTCATCCGGAGTTGTTAATCCAGTAATGGAACCAATTTATGATGAACCGACGACGACTACTAGCGTGCCTTTGTAAGCACAAGCTGATGA GTACGAACTTATGTACTCATTCGTTTCGGAAGAGACAGGTACGTTAATAGTTAATAGCGTACTTCTTTTTCTTGCTTTCGTGGTATTCTTGCTAGTT ACACTAGCCATCCTTACTGCGCTTCGATTG |
| ORF1 | 350 | TGGTGCATCGTGTTGTCTGTACTGCCGTTGCCACATAGATCATCCAAATCCTAAAGGATTTTGTGACTTAAAAGGTAAGTATGTACAAATACCT ACAACTTGTGCTAATGACCCTGTGGGTTTTACACTTAAAAACACAGTCTGTACCGTCTGCGGTATGTGGAAAGGTTATGGCTGTAGTTGTGAT CAACTCCGCGAACCCATGCTTCAGTCAGCTGATGCACAATCGTTTTTAAACGGGTTTGCGGTGTAAGTGCAGCCCGTCTTACACCGTGCGGCA CAGGCACTAGTACTGATGTCGTATACAGGGCTTTTGACATCTACAATGATAAAGTAGCTGGTTTTGCTAA |
| RNP | 119 | GCGGTGTTTGCAGATTTGGACCTGCGAGCGGGTTCTGACCTGAAGGCTCTGCGCGGACTTGTGGAGACAGCCGCTCACCTTGGCTATTCAA AATCCCCTTGCTACTGCTGATCACGCGT |
SARS-CoV-2 Spike Variants
| Description | Configuration | Part # | cGMP |
|---|---|---|---|
| Targets mutations in the SARS CoV-2 spike protein prevalent in the Alpha (B.1.1.7), Beta (B.1.351), Gamma (B.1.1.28), Delta (B.1.617.2), and Omicron (B.1.1.529) strains. | 1x106 cp/mL 250μL | 52160/52154 |
| Target | Size | Sequence |
|---|---|---|
| 1877 | CCCCCTGCATACACTAATTCTTTCACACGTGGTGTTTATTACCCTGACAAAGTTTTCAGATCCTCAGTTTTACATTCAACTCAGGACTTGTTCTTAC CTTTCTTTTCCAATGTTACTTGGTTCCATGCTAT[ACATGTdel]CTCTGGGACCAATGGTACTAAGAGGTTTGATAACCCTGTCCTACCATTTAATG ATGGTGTTTATTTTGCTTCCACTGAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTACTTATTG TTAATAACGCTACTAATGTTGTTATTAAAGTCTGTGAATTTCAATTTTGTAATGATCCATTTTTGGGTGTTTATTACCACAAAAACAACAAAAGTTG GATGGAAAGTGAGTTCAGAGTTTATTCTAGTGCGAATAATTGCACTTTTGAATATGTCTCTCAGCCTTTTCTTATGGACCTTGAAGGAAAACAGG GTAATTTCAAAAATCTTAGGGAATTTGTGTTTAAGAATATTGATGGTTATTTTAAAATATATTCTAAGCACACGCCTATTAATTTAGTGCGTGATCT CCCTCAGGGTTTTTCGGCTTTAGAACCATTGGTAGATTTGCCAATAGGTATTAACATCACTAGGTTTCAAACTTTACTTGCTTTACATAGAAGTTA TTTGACTCCTGGTGATTCTTCTTCAGGTTGGACAGCTGGTGCTGCAGCTTATTATGTGGGTTATCTTCAACCTAGGACTTTTCTATTAAAATATAA TGAAAATGGAACCATTACAGATGCTGTAGACTGTGCACTTGACCCTCTCTCAGAAACAAAGTGTACGTTGAAATCCTTCACTGTAGAAAAAGGAA TCTATCAAACTTCTAACTTTAGAGTCCAACCAACAGAATCTATTGTTAGATTTCCTAATATTACAAACTTGTGCCCTTTTGGTGAAGTTTTTAACGCC ACCAGATTTGCATCTGTTTATGCTTGGAACAGGAAGAGAATCAGCAACTGTGTTGCTGATTATTCTGTCCTATATAATTCCGCATCATTTTCCACTT TTAAGTGTTATGGAGTGTCTCCTACTAAATTAAATGATCTCTGCTTTACTAATGTCTATGCAGATTCATTTGTAATTAGAGGTGATGAAGTCAGACA AATCGCTCCAGGGCAAACTGGAAAGATTGCTGATTATAATTATAAATTACCAGATGATTTTACAGGCTGCGTTATAGCTTGGAATTCTAACAATCTT GATTCTAAGGTTGGTGGTAATTATAATTACCGGTATAGATTGTTTAGGAAGTCTAATCTCAAACCTTTTGAGAGAGATATTTCAACTGAAATCTATC AGGCCGGTAGCACACCTTGTAATGGTGTTAAAGGTTTTAATTGTTACTTTCCTTTACAATCATATGGTTTCCAACCCACTTATGGTGTTGGTTACCA ACCATACAGAGTAGTAGTACTTTCTTTTGAACTTCTACATGCACCAGCAACTGTTTGTGGACCTAAAAAGTCTACTAATTTGGTTAAAAACAAATGT GTCAATTTCAACTTCAATGGTTTAACAGGCACAGGTGTTCTTACTGAGTCTAACAAAAAGTTTCTGCCTTTCCAACAATTTGGCAGAGACATTGCT GACACTACTGATGCTGTCCGTGATCCACAGACACTTGAGATTCTTGACATTACACCATGTTCTTTTGGTGGTGTCAGTGTTATAACACCAGGAACA AATACTTCTAACCAGGTTGCTGTTCTTTATCAGGGTGTTAACTGCACAGAAGTCCCTGTTGCTATTCATGCAGATCAACTTACTCCTACTTGGCGTG TTTATTCTACAGGTTCTAATGTTTTTCAAACACGTGCAGGC |
| Target | Size | Sequence |
|---|---|---|
| N | 1877 | CCCCCTGCATACACTAATTCTTTCACACGTGGTGTTTATTACCCTGACAAAGTTTTCAGATCCTCAGTTTTACATTCAACTCAGGACTTGTTCTT ACCTTTCTTTTCCAATGTTACTTGGTTCCATGCTAT[ACATGTdel]CTCTGGGACCAATGGTACTAAGAGGTTTGATAACCCTGTCCTACCATTT AATGATGGTGTTTATTTTGCTTCCACTGAGAAGTCTAACATAATAAGAGGCTGGATTTTTGGTACTACTTTAGATTCGAAGACCCAGTCCCTAC TTATTGTTAATAACGCTACTAATGTTGTTATTAAAGTCTGTGAATTTCAATTTTGTAATGATCCATTTTTGGGTGTTTATTACCACAAAAACAACA AAAGTTGGATGGAAAGTGAGTTCAGAGTTTATTCTAGTGCGAATAATTGCACTTTTGAATATGTCTCTCAGCCTTTTCTTATGGACCTTGAAGG AAAACAGGGTAATTTCAAAAATCTTAGGGAATTTGTGTTTAAGAATATTGATGGTTATTTTAAAATATATTCTAAGCACACGCCTATTAATTTAG TGCGTGATCTCCCTCAGGGTTTTTCGGCTTTAGAACCATTGGTAGATTTGCCAATAGGTATTAACATCACTAGGTTTCAAACTTTACTTGCTTTA CATAGAAGTTATTTGACTCCTGGTGATTCTTCTTCAGGTTGGACAGCTGGTGCTGCAGCTTATTATGTGGGTTATCTTCAACCTAGGACTTTTC TATTAAAATATAATGAAAATGGAACCATTACAGATGCTGTAGACTGTGCACTTGACCCTCTCTCAGAAACAAAGTGTACGTTGAAATCCTTCAC TGTAGAAAAAGGAATCTATCAAACTTCTAACTTTAGAGTCCAACCAACAGAATCTATTGTTAGATTTCCTAATATTACAAACTTGTGCCCTTTTG GTGAAGTTTTTAACGCCACCAGATTTGCATCTGTTTATGCTTGGAACAGGAAGAGAATCAGCAACTGTGTTGCTGATTATTCTGTCCTATATAA TTCCGCATCATTTTCCACTTTTAAGTGTTATGGAGTGTCTCCTACTAAATTAAATGATCTCTGCTTTACTAATGTCTATGCAGATTCATTTGTAAT TAGAGGTGATGAAGTCAGACAAATCGCTCCAGGGCAAACTGGAAAGATTGCTGATTATAATTATAAATTACCAGATGATTTTACAGGCTGCGT TATAGCTTGGAATTCTAACAATCTTGATTCTAAGGTTGGTGGTAATTATAATTACCGGTATAGATTGTTTAGGAAGTCTAATCTCAAACCTTTTG AGAGAGATATTTCAACTGAAATCTATCAGGCCGGTAGCACACCTTGTAATGGTGTTAAAGGTTTTAATTGTTACTTTCCTTTACAATCATATGGT TTCCAACCCACTTATGGTGTTGGTTACCAACCATACAGAGTAGTAGTACTTTCTTTTGAACTTCTACATGCACCAGCAACTGTTTGTGGACCTAA AAAGTCTACTAATTTGGTTAAAAACAAATGTGTCAATTTCAACTTCAATGGTTTAACAGGCACAGGTGTTCTTACTGAGTCTAACAAAAAGTTTCT GCCTTTCCAACAATTTGGCAGAGACATTGCTGACACTACTGATGCTGTCCGTGATCCACAGACACTTGAGATTCTTGACATTACACCATGTTCTT TTGGTGGTGTCAGTGTTATAACACCAGGAACAAATACTTCTAACCAGGTTGCTGTTCTTTATCAGGGTGTTAACTGCACAGAAGTCCCTGTTGCT ATTCATGCAGATCAACTTACTCCTACTTGGCGTGTTTATTCTACAGGTTCTAATGTTTTTCAAACACGTGCAGGC |
Respiratory Triplex
| Description | Configuration | Part # | cGMP |
|---|---|---|---|
| Contains regions of SARS-Cov-2, Influenza A (H1N1, H3N2, and H7N9), Influenza B, Respiratory Syncytial Virus A (RSVA), Respiratory Syncytial Virus B (RSVB), and RPP30 as an internal control. | 1x108 cp/mL 250μL | 52108 |
| Target | Size | Sequence |
|---|---|---|
| CoV-2 | 1001 | GAACAAACTAAAATGTCTGATAATGGACCCCAAAATCAGCGAAATGCACCCCGCATTACGTTTGGTGGACCCTCAGATTCAACTGGCAGTAA CCAGAATGGAGAACGCAGTGGGGCGCGATCAAAACAACGTCGGCCCCAAGGTTTACCCAATAATACTGCGTCTTGGTTCACCGCTCTCACT CAACATGGCAAGGAAGACCTTAAATTCCCTCGAGGACAAGGCGTTCCAATTAACACCAATAGCAGTCCAGATGACCAAATTGGCTACTACCG AAGAGCTACCAGACGAATTCGTGGTGGTGACGGTAAAATGAAAGATCTCAGTCCAAGATGGTATTTCTACTACCTAGGAACTGGGCCAGAA GCTGGACTTCCCTATGGTGCTAACAAAGACGGCATCATATGGGTTGCAACTGAGGGAGCCTTGAATACACCAAAAGATCACATTGGCACCC GCAATCCTGCTAACAATGCTGCAATCGTGCTACAACTTCCTCAAGGAACAACATTGCCAAAAGGCTTCTACGCAGAAGGGAGCAGAGGCGG CAGTCAAGCCTCTTCTCGTTCCTCATCACGTAGTCGCAACAGTTCAAGAAATTCAACTCCAGGCAGCAGTAGGGGAACTTCTCCTGCTAGAAT GGCTGGCAATGGCGGTGATGCTGCTCTTGCTTTGCTGCTGCTTGACAGATTGAACCAGCTTGAGAGCAAAATGTCTGGTAAAGGCCAACAAC AACAAGGCCAAACTGTCACTAAGAAATCTGCTGCTGAGGCTTCTAAGAAGCCTCGGCAAAAACGTACTGCCACTAAAGCATACAATGTAACAC AAGCTTTCGGCAGACGTGGTCCAGAACAAACCCAAGGAAATTTTGGGGACCAGGAACTAATCAGACAAGGAACTGATTACAAACATTGGCCG CAAATTGCACAATTTGCCCCCAGCGCTTCAGCGTTCTTCGGAATGTCGCGCATTGGCATGGAAGTCACACCTTCGGGAACGTG |
| Flu | 1430 | ACGCGTGATCAGCAGAAGCAGGGGTTTAATTCTCATGGAATGGCTAAAGACAAGACCAATCTTGTCACCTCTGACTAAGGGAATTTTAGGA TTTGTGTTCACGCTCACCGTGCCCAGTGAGCGAGGACTGCAGCGTAGACGCTTTATCCAAAATGCCCTAAATGGAAATGGGGACCCGAACA ACATGGATAGAGCAGTTAAACTATACAAGAAGCTCAAAAGAGAAATAACATTCCATGGGGCCAAGGAGGTGTCACTAAGCTATTCAACTGGT GCACTTGCAAGTTGCATGGGCCTCATATACAACAGAATGGGAACAGGCCTGCTTGTGTGTATGGGCTTGCAGTAGCAAGTGGCCATGACTTT GAAAGGGAAGGGTACTCACTGGTCGGGATAGACCCATTCAAATTACTCCAAAACAGTCAAGTGGTCAGCCTGATGAGACCAAATGAAAATCC AGCTCACAAGAGTCAATTGGTATGGATGGCATCAACTTGTCAGACAGCCGAGGGTGCTATAAACACCAGCCTCCCATTTCAGAATGTACATCC GGTCACAATTGGGAAATGTCCAAAGTATGTAAAAAGCACAAAATTGAGGCTGGCCACAGGATTGAGGAATGTCCCGTCTATTCAATCTAGAGG CCTATTCTGAATGCATCACTCCAAATGGAAGCATTCCCAATGACAAACCATTCCAAAATGTAAACAGGATCACATACGGGGCCTGTCCCAGATA TGTTAAGCATAGCACTCTGAAATTGGCAACAGGAATGAGAAATATACCAGAGAAACAAACTAGGGGCATATTTGGCGCAATAGCGGGTTTCAT AGAAAATGGGGTATGGTTTCAGACACCAGAATGCACAGGGAGAGGGAACTGCTGCAGATTACAAAAGCACTCAATCGGCAATTGATCAAATA ACAGGGAAATTAAACCGGCTTATAGCAAAAACCAACCAACAATTTAAGTTGATAGACAATGAATTCAATGAGGTAGAGAAGCAAATCGGTAATG TGATAAATTGGACCAGAGATTCTATAACAGAAGTATGGTCATACAATGCTGAACTCTTGGTGGCAATGGAGAACCAGCATACAATTGAGAGGAT GAAGAAGATGGCCATCGGATCCTCAACTCACTCTTCGAGCGTCTCAATGAAGGACATTCAAAGCCAATTCGAGCAGCTGAAACTGCGGTGGGA GTCTTATCCCAATTTGGTCAAGAGCACCGATTATCACCAGAAGAGGGAGACCAATGGTTTTGTGCTCGGCAGATGGGAGAGATGGTGTGGAGA TATAAAGACCACAATTATGCCTGAAATTGACTCGATGGAAAAAGATATTGCCCTCTCTAGGGAGAGACTTGACCTGGGAGAGGATGCCCCTGAC GAAACCGACAACTCACCAATTCCTTTTTCCAATGATGGC |
| RSVA | 589 | CCTGTGAATATGGGAGGTTTCATCAAATGTATCTCATTAAGCTTAGGTATGAGAATAATTCTGTTAGGACATACATTAGTAAATTGTTCTACTAC TGACATTAAACTAAGGCCAAAGCTTATACAGTTTTGGAATACTATGTCAATATCTTCATCACCATACTTTTCTGTTAATATGCGATTAATAGGGCT AGTGTCAAAGTGATAATTTGTTGTTCTATAAGCTGGTATTGATGCAGGGAATTCACATGGTCTACTACTGACTGTAAGGCGATGCAAATAATTG ACACTTAAATATTGTGGAAATAATTTCTTGGCCTTTTCATATGTTAACCCAAGGGTTCCTATGCTGAGTTCTTCCATGAATTCATCCTTGTTATCTA TAGATGCATACACCCAATCCAATTTTGCTAATAGATCTATTTGATCTCTCTGTTTTTTTGGTTAAGACTTGTCTATTATAAACTGGCATTGTTTTTTT CTCTTGTGTAGATGAACCAACCCATGGTTTAGTGGGTCCTCTCTCACCACGTGTTAAACTGTTAACATTATATTTCTCTATAATTATGCCACTAGA TATAGTGCTTGTA |
| RSVB | 383 | TGATGATTTTTGATCAGTGATCAACTCACTCAGCAATCAACAACATCAATAAAACAGACACCAATCCATTGAATCAATTGCCAGACTGAAAAAA CAAACATCCATCAGCAGAACCACCAACCAATCAATCAACCAATTGATCAATCAGCACCCTGACAAAATTAACAATATAGTAACAAAAAAAGAAC AAGATGGGGCAAATATGGAAACATACGTGAACAAGCTTCACGAAGGCTCCACATACACAGCAGCTGTTCAGTACAATGTTCTAGAAAAAGAT GATGATCCCGCATCACTAACAATATGGGTGCCTATGTTCCAGTCATCTGTGCCAGCAGACTTGCTCATAAAAGAACTTGCAAGCATCAACATA CTGGTAAAGC |
| RNP | 119 | GCGGTGTTTGCAGATTTGGACCTGCGAGCGGGTTCTGACCTGAAGGCTCTGCGCGGACTTGTGGAGACAGCCGCTCACCTTGGCTATT CAAAATCCCCTTGCTACTGCTGATCACGCGT |
Armored RNA Quant® EPA 1615 Controls
| Description | Configuration | Part # | cGMP |
|---|---|---|---|
| Contains sequences detected by the Enterovirus, Norwalk GI, and Norwalk GII virus assays described in EPA Method 1615 - Measurement of Enterovirus and Norovirus occurrence in water by culture and RT-qPCR. | 1x1012 cp/mL 500μL | 52000 |
| Target | Size | Sequence |
|---|---|---|
| Nor-1 | 96 | G CCATGTTCCGCTGGATGCGCTTCCATGACCTCGGATTGTGGACAGGAGATCGCGATCTTCTGCCCGAATTCGTAAATGATGATGGCGTCTAAGG |
| Nor-2 | 91 | A ATGTTCAGATGGATGAGATTCTCAGATCTGAGCACGTGGGAGGGCGATCGCAATCTGGCTCCCAGCTTTGTGAATGAAGATGGCGTCGA |
| EV | 196 | C CTCCGGCCCCTGAATGCGGCTAATCCCAACCTCGGGGCAGGTGGTCACAAACCAGTGATTGGCCTGTCGTAACGCGCAAGTCCGTGGCGGAA CCGACTACTTTGGGTGTCCGTGTTTCCTTTTATTTTATTGTGGCTGCTTATGGTGACAATCACAGATTGTTATCATAAAGCGAATTGGATTGGCCATC CGGT |
Enterovirus
| Description | Configuration | Part # | cGMP |
|---|---|---|---|
| Contains sequences amplified by primer binding regions for polio virus (type I Sabin), coxsackievirus A and coxsackievirus B (Schwab, et al., 1995 and Rotbart, 1990). | 5x105 cp/mL 5x100μL | 42102 | ● |
| Target | Size | Sequence |
|---|---|---|
| 263 | TGAGCTACATAAGAATCCTCCGGCCCCTGAATGCGGCTAATCCCAACCTCGGGGCAGGTGGTCACAAACCAGTGATTGGCCTGTCGTAACGCGC AAGTCCGTGGCGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTTATTTTATTGTGGCTGCTTATGGTGACAATCACAGATTGTTATCATAAAGCG AATTGGATTGGCCATCCGGTGAAAGTGAGATTCATTATCTATCTGTTTGCTGGATTCGCTCCATTGAGTGTG |
Pentavalent Arbovirus Control
(CHIKV,DENV,WNV,YFV,ZIKV)
| Description | Configuration | Part # | cGMP |
|---|---|---|---|
| Targets regions of the Chikungunya, Dengue, West Nile, Yellow Fever, and Zika viruses. | 1x108 cp/mL 500μL | 49659 | ● |
| Target | Size | Sequence |
|---|---|---|
| 2200 | CCGACTCAACCATCCTGGATTTGCCAGCAAGGAGGATGATGTCGGACAGGAAGTACCACTGCGTCTGCCTTCATCTGCACCCAAGTGTACCATT GCGGTGTACACTGCCTGTGACCGCTTCATTACGAAGGCAAAATGCGCTTGAGCATATGGTTACGCAGATAGTTACGAGTCATCTGCGTATTGGG ACGCATTGAAACCACCATGTGTCACCAGCATTTGTACTGGCAGCAGCCACGTTAACGTCACACAGATGAGTTGAATTTGCTGCCAGCCCTATTTC GAAAAGGAACCGGAGGAAACCCTACGCATGCTTGATTAACGTCATGAGACCTGGGTACTATCTTAAGCTCCGCGTCCTTTACCAAGTTCCAATGT CTTCAGCCTGGACACCTTTTTAGGAAGACCAGGACAATTTGGTTGTCACATACCACCCTCGTTGGGACTGGTTGTTGCTGTTGCCGCTTAGGTAT ATGTGTCCCCTAAGAGACATTCAGATCTCTGATGAACAACCAACGTTATATGCTGAAACGCGCGAGTTGTTGGCGAAGAGATTCTCAAATTCAAA AGGAAGTCGTGCAATATTCATGTGGCTGGGAGCACGCTTGTTTAGTAGAGAGAATTCACTCAGTTGACTAGTGGTTAGAGGAGACCCCTCCCTT AAGGACTAGAGGTTAGAGGAGACCCCCTTACAGCATATTGACGCTGGGAGAGACCAGAGATCCTGCTGTCTCTACAGCATCATTCCAGGCACA GAACGCCAGAAAATGGAATGGTTTAGTAGTTCGCCTGTGTGAGCTGACAAACTTAGTAGTGTTTGTGAGGATTTTTGCGAGCTGTTTCTTAGCAC GAAGATCTCGATGTCTAAGAAACCAGGAGGGCTTGGCTGTCAATATGCTAAAACGCTTCTACCGTCAGCGATCTCTTCATGGGAGAAGCTCACTT CAAACGTGCTGACCCAGTTCCTTTTCAGTTGGGCCTTCTGGTCGTGTTCTTCCACCCAGGAGGTCCTTCGCAAGAGGTGGACAGCCAAGATCAGC ATGCCAGCTTTTGGGGGCATTACTTACACTGTTCGCTGTCCCTGTGAATTGTTTGGTCCATCCATGCAGGAGGAGAGTTGTCTGGAACCGTGTTTG GTTCCACCGGAAGTTGAGTAGACGGTGCTGCCTGCGACTCAACCCCAGGAGGACTGGGTGAACAAATTCCATGTAAGCCCTCAGAACCGTCTCG GAAGGTTGCTAATTGAGGTGCATTGGTCTGCAAATCGAGTTGCTAGGCAATAAACACTTATCGTTCGTTGAGCGATTAGCAGAGAACTGACTTTCT GGTCGTAAAGCTCAGGGATTACAACATGATGGGGAAAAGAGAGAATTTGGTACATGTGGCTGGGAGCTTCGCGGATGACACCGCTGGATGGGA CACGTGCACGGATGTGACAGACTGAAAATTCGATTGTGTTGTCCGGCCCATCGATGACAGGTTCGGCCTGGTTTGGTCATGATACTGCTGATTGC CCCGGCATATAGCATCAGGTGCATAGGAGTCAGCAATAGGGACTTTGTGGAAGGTAGCCGCTGCCCAACACAAGGTGAAGCCTACCTTGACAAG CAATCAGACACTCAATATGTCTGCAAAAGAACGTTAGTGGTTTGGCAAAGGGAGCCTGGTGTAAGTTTGCATGCTCCAAGAAAATTACCGGGAAG AGCATCCAGCCAGATATCTGGAGTACCGGATAATGCTGTCAACCACTGCAAGCGGAAGGTTATGGTGCTGCAGGGAGTGCACAATGCCCCCACT GTCGTTCCGGGCTAAAGATGGCTGTTGGTATGGAATGGAGATAAGGCCCATCTGTGGCATGAACCCAATAGTCCTTTGCAGCTGGAGCGTGGTG GAGTGGTGCTCTATGGGATTCAGCTGGCATCATGAAGAACCCTGTTGTGGATGGAATAGTGGTTGGAGAAAAAGATGGGACAGGTGTTACGCTC AGAGTCCTCTCCATGTTTGTGCCCATACACCAGTTGATGGAAACCCTGGAGCGACTTAAGTACACATACCAAAACAAAGTGGTTTCTTAGACCAGC TGAAATTCAAGACCAAAGGGGGAGCGGATCTCAATGTTGTCAGGCCTGCTAGTCAGCCACAGTTTGGGGAAAGCTGTGCAGCCTGTAACCCCCC CAGGAGAAGCTGGGAAATCAAGCTC |
Internal Process Control (Armored RNA Quant)
| Description | Configuration | Part # | cGMP | |
|---|---|---|---|---|
| Targets a non-specific, 1,000 nucleotides in vitro transcribed RNA (non-homologous) sequence intended to be used as a spike-in to sample (e.g., urine, blood, CSF, plasma/liquid biopsy) to monitor the overall efficiency of a testing process. | 2x106 cp/mL 500μL | 49650 |
| Target | Size | Sequence |
|---|---|---|
| 1000 | GTACTGACGTAAAGTCACTATTTTTCGTGCAACGTACGTCTCGATGTACAACTGCTCTATTACGGTTCATTTTTTTTGTAGGGTTACGCGGCCA GATGACTCCATCTTATCCCCTTGAAAACATTCTTATTTGTACGCCATAGTGGCATCGCGGTTGGATATCAATCGTATTGGACGCAAGCGCGCT CTACTCAGTTTATAAGACCGCCAACTATTTTCGCAAGATCAGTGTATTTACGCTGACTCCAGTGGTGAAACTCCTAAGATCTGTTTAGCTATTG CGCCGTGCGTTTATCAAATCGGGCTTCCCAACATTCATTCTTAGAAGGAAGCTCGATAGTTCAGAGCTGCGGAAGGCCCAATTTCATATTATA TGTATGAGCCTGTCAATACCTGCACCCACGAACACCACAGTGACTAGAGTATGAGAGGTCGACGATCTACGGATGGTGATGAGCACGGAGAT CTAAGCGTGGAAGTGGCTATATAGAGCAGATATATTATATGACGTACCAGAGGATCACCTACTAAAAGACTTTTCGAGAATCTACACCTACTAG CAAGGGTAGCCGATTAGTGGATCATCTAAGACATCAAGGCTCAAACTAATTTTACCATGGACGCTGCATTTACGCTTGCACATTTTATGTTGGCA GCCTTTGCCGCGGCACATAGCGATATCCCGTACCCGCTTTTCTTTAAGTTAATCGCCGATGATTGGCTCAATAATCGCCTCACTTGTGCGATGAC TAGCCAGGCGTTTCCCGCGTTTCTAGATATTATCGCGCTTATATAGTATAGACGAGTACCCTTTGTTGTTATTGCAGCACCCAACAGAACTAAGTA ATCTTTAGGCTGCGGCCGCTTAGGTGGCAGAAGATTTGCTCGATGTTCTCAAGTAAAGGACGTCGGGGAGTTGACGGTTGGCAGGTAACGTATG GATCTTTAATATAATCTAGGCAACAAGTAAGGGCCATTGAGCGCTTATATGCCGCAGTCT |
RNase P
| Description | Configuration | Part # | cGMP |
|---|---|---|---|
| Targets the human RNase P gene; often used as an internal control because abundant copies in the human genome make it readily detectable. | 1x106 cp/mL 500μL | 52152 |
| Target | Size | Sequence |
|---|---|---|
| 144 | GAATTCGGCACGAGGTGGGACTTCAGCATGGCGGTGTTTGCAGATTTGGACCTGCGAGCGGGTTCTGACCTGAAGGCTCTGCGCGGACTT GTGGAGACAGCCGCTCACCTTGGCTATTCAGTTGTTGCTATCAATCATATCGTT |
Mpox Nonvariola Orthopox Control
| Description | Configuration | Part # | cGMP |
|---|---|---|---|
| A single, concatenated construct of both nonvariola Orthopox and Mpox-specific sequence blended with with RNAse P to allow for an all-in-one process control. The control is provided as two tubes of high and low concentration along with diluent for convenience. | 500μL | 49670 | ● |
| Target | Size | Sequence |
|---|---|---|
| NVO/MPX | 300 | ATAATAAACGGAAGAGATATAGCACCACATGCACCATCCAATGGAAAATGTAAAGACAACGAATACAGAAGCCGTAATCTATGTTGTCTAT CGTGTCCTCCGGGAACTTACGCTTCCAGATTATGTGATAGCAAGACTAATACACAATGTACGCCTAAAACAGGCTACCAGTTCAACTGAAA AGGCCATCTATGATTCCATGCAATATACGTACAAGATAGTAGCCAACTCAGTATATGGTCTGATGGGATTTAGAAATAGTGCTCTATACTCA TACGCTTCGGCTAAGAGTTGCACATC |
| RNP | 144 | GAATTCGGCACGAGGTGGGACTTCAGCATGGCGGTGTTTGCAGATTTGGACCTGCGAGCGGGTTCTGACCTGAAGGCTCTGCGCGGACT TGTGGAGACAGCCGCTCACCTTGGCTATTCAGTTGTTGCTATCAATCATATCGTT |
Internal Process Control (Armored DNA Quant)
| Description | Configuration | Part # | cGMP |
|---|---|---|---|
| Targets a non-specific, 495 base pair in vitro transcribed DNA (non-homologous) sequence intended to be used as a spike-in to sample (e.g., urine, blood, CSF, plasma/liquid biopsy) to monitor the overall efficiency of a testing process. | 1x108 cp/mL 500μL | 52003 |
| Target | Size | Sequence |
|---|---|---|
| 495 | GACATCAAGGCTCAAACTAATTTTACCATGGACGCTGCATTTACGCTTGCACATTTTATGTTGGCAGCCTTTGCCGCGGCACATAGCGATATCC CGTACCCGCTTTTCTTTAAGTTAATCGCCGATGATTGGCTCAATAATCGCCTCACTTGTGCGATGACTAGCCAGGCGTTTCCCGCGTTTCTAGA TATTATCGCGCTTATATAGTATAGACGAGTACCCTTTGTTGTTATTGCAGCACCCAACAGAACTAAGTAATCTTTAGGCTGCGGCCGCTTAGGTG GCAGAAGATTTGCTCGATGTTCTCAAGTAAAGGACGTCGGGGAGTTGACGGTTGGCAGGTAACGTATGGATCTTTAATATAATCTAGGCAACA AGTAAGGGCCATTGAGCGCTTATATGCCGCAGTCTAAACATGAGGATTACCCATGTAAGCTTATTCCCTTTAGTGAGGGTTAATTTTAGCTTGGC ACTGGCCGTCGTTTTACAACGTCG |
Hepatitis G Virus
| Description | Configuration | Part # | cGMP |
|---|---|---|---|
| Contains sequences amplified by primer binding regions for Hepatitis G Virus (Schlueter, 1996); the PCR product generated is 185 nucleotides. | 250μL | 42024 | ● |
| Target | Size | Sequence |
|---|---|---|
| 263 | CCGGCACTGGGTGCAAGCCCCAGAAACCGACGCCTATTTTAAACAGACGTTATGAACCGGCGCTGACTCGGCGACCGGCCAAAAGGTGGTGG ATGGGTGATGCCAGGGTTGGTAGGTCGTAAATCCCGGTCATCTTGGTAGCCACTATAGGTGGGTCTTAAGGGTTAGTCAAGGTCCCTCTGGCG CTTGTGGCGAGAAGCGCACGGTCCACAGGTGTTGGCCCTACCGGTGTGAATAAGGGCCCGACGTCAGGCTCGTCGTTAAACCGAGCCCATTA CCCACCTGGGCAAACGACGCCCACGTACGGTCCACGTCGCCCTTCAATGTCTCTCTTGACCAATAGGCTTAGCCGGCGAGTTGACAAGGACCA |
Enterovirus
| Description | Configuration | Part # | cGMP |
|---|---|---|---|
| Contains sequences amplified by primer binding regions for polio virus (type I Sabin), coxsackievirus A and coxsackievirus B (Schwab, et al., 1995 and Rotbart, 1990). | 250μL | 42050 | ● |
| Target | Size | Sequence |
|---|---|---|
| 263 | TGAGCTACATAAGAATCCTCCGGCCCCTGAATGCGGCTAATCCCAACCTCGGGGCAGGTGGTCACAAACCAGTGATTGGCCTGTCGTAACGCG CAAGTCCGTGGCGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTTATTTTATTGTGGCTGCTTATGGTGACAATCACAGATTGTTATCATAAA GCGAATTGGATTGGCCATCCGGTGAAAGTGAGATTCATTATCTATCTGTTTGCTGGATTCGCTCCATTGAGTGTG |
Bacteriophage MS2
| Description | Part # |
|---|---|
| Bacteriophage MS2 | 52223 |
Beta-Actin (ACTB)
| Description | Part # |
|---|---|
| Beta-Actin (ACTB) | 52225 |
Ebolavirus
| Description | Part # |
|---|---|
| Ebolavirus | 52217 |
Glucuronidase Beta (GUSB)
| Description | Part # |
|---|---|
| Glucuronidase Beta (GUSB) | 52224 |
Hepatitis C Virus (GT 2b)
| Description | Part # |
|---|---|
| Hepatitis C Virus (GT 2b) | 42101 |
Hepatitis D Virus
| Description | Part # |
|---|---|
| Hepatitis D Virus | 52212 |
HIV (Subtype B)
| Description | Part # |
|---|---|
| HIV (Subtype B) | 42103 |
Human Papillomavirus 16
| Description | Part # |
|---|---|
| Human Papillomavirus 16 | 52219 |
Human Papillomavirus 18
| Description | Part # |
|---|---|
| Human Papillomavirus 18 | 52220 |
Sapovirus I, II, IV
| Description | Part # |
|---|---|
| Sapovirus I, II, IV | 52221 |
Sapovirus V
| Description | Part # |
|---|---|
| Sapovirus V | 52222 |
Sudan Ebolavirus
| Description | Part # |
|---|---|
| Sudan Ebolavirus | 52218 |
Dengue Virus (Type I)
| Description | Part # |
|---|---|
| Dengue Virus (Type I) | 42044 |
Hepatitis C Virus (GT 1a)
| Description | Part # |
|---|---|
| Hepatitis C Virus (GT 1a) | 42004 |
Hepatitis C Virus (GT 1b)
| Description | Part # |
|---|---|
| Hepatitis C Virus (GT 1b) | 42006 |
Hepatitis C Virus (GT 2a/c)
| Description | Part # |
|---|---|
| Hepatitis C Virus (GT 2a/c) | 42008 |
Hepatitis C Virus (GT 2b)
| Description | Part # |
|---|---|
| Hepatitis C Virus (GT 2b) | 42010 |
Hepatitis C Virus (GT 3a)
| Description | Part # |
|---|---|
| Hepatitis C Virus (GT 3a) | 42012 |
HIV (Subtype B)
| Description | Part # |
|---|---|
| HIV (Subtype B) | 42000 |
Norovirus GI
| Description | Part # |
|---|---|
| Norovirus GI | 42030 |
Norovirus GII
| Description | Part # |
|---|---|
| Norovirus GII | 42032 |
SARS (BNI-1)
| Description | Part # |
|---|---|
| SARS (BNI-1) | 42090 |
SARS (CoV-NC)
| Description | Part # |
|---|---|
| SARS (CoV-NC) | 42091 |
West Nile Virus (Cap)
| Description | Part # |
|---|---|
| West Nile Virus (Cap) | 42042 |
West Nile Virus (HNY1999)
| Description | Part # |
|---|---|
| West Nile Virus (HNY1999) | 42040 |
West Nile Virus (NEN)
| Description | Part # |
|---|---|
| West Nile Virus (NEN) | 42041 |
RNARetain Buffer
| Description | Part # | Configuration |
|---|---|---|
| Intended for the collection, storage, and transportation of fresh tissue specimens for subsequent RNA isolation and further molecular testing. Eliminates the need to immediately process specimens, enabling RNA extraction and molecular testing at a later time and/or transport to a different location. | 49536 | Volume 2L† |
†Variable concentrations, volumes and vial quantities available upon request
TSMIII Buffer
| Description | Part # | Configuration |
|---|---|---|
| A buffered solution ideally suited for the dilution of Armored products. The additives provide stability to the protein-coated nucleic acid through multiple freeze-thaws when stored properly, allowing for more flexible and scalable testing processes. | 49600 | Volume 50mL |